Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

Porto Alegre 90110-270

6 studies enrolling now · 9 studies all time

What they study most

Advanced Solid Tumor, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, B-cell Malignancy, CLL, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Extragonadal Yolk Sac Tumors, Follicular Lymphoma, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Studies at this site

• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — Recruiting now
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — Recruiting now
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia — Recruiting now
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling